Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$32.4 - $68.18 $729,907 - $1.54 Million
-22,528 Reduced 0.47%
4,749,863 $323 Million
Q2 2022

Aug 12, 2022

SELL
$22.3 - $37.39 $11.4 Million - $19.1 Million
-512,120 Reduced 9.69%
4,772,391 $152 Million
Q1 2022

May 12, 2022

SELL
$25.68 - $35.59 $1.76 Million - $2.44 Million
-68,545 Reduced 1.28%
5,284,511 $183 Million
Q4 2021

Feb 10, 2022

SELL
$24.9 - $40.26 $10.4 Million - $16.8 Million
-418,159 Reduced 7.25%
5,353,056 $157 Million
Q3 2021

Nov 09, 2021

BUY
$25.48 - $37.34 $25,046 - $36,705
983 Added 0.02%
5,771,215 $147 Million
Q2 2021

Aug 11, 2021

BUY
$32.46 - $43.42 $187 Million - $251 Million
5,770,232 New
5,770,232 $202 Million

Others Institutions Holding GBT

About Global Blood Therapeutics, Inc.


  • Ticker GBT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,476,200
  • Market Cap $4.62B
  • Description
  • Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...
More about GBT
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.